Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients

References

• Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, . Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632–41.
   PubMed Web of Science ®Google Scholar
• Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, . Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52:1035–40.
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, . Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839–48.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975–82.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65.
   PubMed Web of Science ®Google Scholar
• Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, . Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972–82.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438–50.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008;48:353–67.
   PubMed Web of Science ®Google Scholar
• Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008;47: 94–101.
   PubMed Web of Science ®Google Scholar
• Karlstrom O, Sonnerborg A, Weiland O. Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy. AIDS 2008;22:899–901.
   PubMedGoogle Scholar
• Moreno A, Barcena R, Garcia-Garzon S, Muriel A, Quereda C, Moreno L, . HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin. J Hepatol 2005;43:783–90.
   PubMed Web of Science ®Google Scholar
• Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, . Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42: 615–24.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, . European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82–8.
   PubMed Web of Science ®Google Scholar
• Lagging M, Wejstal R, Uhnoo I, Gerden B, Fischler B, Friman S, . Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009;41:389–402.
   PubMed Web of Science ®Google Scholar
• Anonymous. Läkemedelsbehandling av kronisk hepatit C hos vuxna och barn—Uppdaterad rekommendation. Information från Läkemedelsverket (Information from the Swedish Medical Product Agency) 2008;6:14–26.
   Google Scholar
• Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, . A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395–403.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, . Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004;99: 1298–305.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, . Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580–93.
   PubMed Web of Science ®Google Scholar
• Shin WG, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, . Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008;40:267–74.
   PubMedGoogle Scholar
• Westin J, Ydreborg M, Islam S, Alsio A, Dhillon AP, Pawlotsky JM, . A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol 2007;18:1–8.
   Google Scholar
• Sizmann D, Boeck C, Boelter J, Fischer D, Miethke M, Nicolaus S, . Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007;38:326–33.
   PubMed Web of Science ®Google Scholar
• Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259–66.
   PubMed Web of Science ®Google Scholar
• Yun Z, Lara C, Johansson B, Lorenzana de Rivera I, Sonnerborg A. Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. J Med Virol 1996;49:155–60.
   PubMed Web of Science ®Google Scholar
• Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, . Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008;15:641–5.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, . Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061–9.
   PubMed Web of Science ®Google Scholar